High-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of age. However, promising data on the use of combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) in this population have raised questions about the role and timing of transplantation.
T h e ne w e ngl a nd jou r na l o f m e dicine F or the past 20 years, high-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of age. [1] [2] [3] However, this treatment requires hospitalization and can be associated with substantial toxic effects.
Over the past decade, immunomodulatory drugs [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and proteasome inhibitors [15] [16] [17] have been shown to have substantial activity in patients with multiple myeloma. The use of combination therapy with immunomodulatory drugs, proteasome inhibitors, and dexamethasone has yielded increased rates of complete response and improved outcomes, both among patients who are eligible for transplantation and among those who are not. [18] [19] [20] [21] The observed benefits of these combination therapies have led investigators to propose their use in adults with newly diagnosed multiple myeloma and have raised questions about the role and timing of transplantation in the initial treatment of such patients.
To address these issues, we conducted a phase 3 trial to compare the efficacy and safety of combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) alone with the efficacy and safety of RVD plus autologous stem-cell transplantation for the treatment of newly diagnosed multiple myeloma in adults up to 65 years of age.
Me thods

Criteria for Enrollment
Eligible patients were 65 years of age or younger and presented with symptomatic, measurable, newly diagnosed multiple myeloma. (The terms symptomatic and measurable are defined in the study protocol, available with the full text of this article at NEJM.org.) Additional eligibility criteria were serum levels of aspartate aminotransferase and alanine aminotransferase of no more than 2 times the upper limit of the normal range, a serum bilirubin level of no more than 35 μmol per liter (2 mg per deciliter), creatinine clearance of at least 50 ml per minute, an absolute neutrophil count of at least 1000 per cubic millimeter, a platelet count of more than 50,000 per cubic millimeter, and normal cardiac and pulmonary function. Main exclusion criteria were peripheral neuropathy of grade 2 or higher and a history of other cancer. Women of childbearing potential were eligible if they agreed to use contraception, produced evidence of a negative pregnancy test before enrollment, and agreed to undergo monthly pregnancy testing until 4 weeks after discontinuation of the study medication. The protocol was approved by the institutional ethics committee at the coordinating center (Purpan Hospital, Toulouse, France). All the patients provided written informed consent.
Trial Design and Treatment
This randomized, open-label, phase 3 trial was conducted at 69 centers in France, Belgium, and Switzerland. Patients were recruited from November 2010 through November 2012 and were randomly assigned, in a 1:1 ratio, to one of two treatment groups during the first cycle of induction therapy. Randomization was stratified according to International Staging System disease stage (stage I, II, or III, with higher stages indicating more severe disease) and cytogenetic risk profile (standard risk, high risk, or risk undetermined because of test failure; high risk was defined by the presence of a t [4;14] translocation, t [14;16] translocation, or 17p deletion, as determined by fluorescence in situ hybridization).
All the patients received induction therapy with three 21-day cycles of RVD, which consisted of lenalidomide (25 mg, administered orally on days 1 through 14), bortezomib (1.3 mg per square meter of body-surface area, administered intravenously on days 1, 4, 8, and 11), and dexamethasone (20 mg, administered orally on days 1, 2, 4, 5, 8, 9, 11, and 12). After the induction phase, all the patients underwent stem-cell mobilization with cyclophosphamide and granulocyte colony-stimulating factor. During the consolidation phase, the patients received either five cycles of RVD with a reduced daily dose of dexamethasone of 10 mg (RVD-alone group) or melphalan at a dose of 200 mg per square meter plus autologous stem-cell transplantation followed by two cycles of RVD with a reduced daily dose of dexamethasone of 10 mg (transplantation group). In both treatment groups, maintenance therapy with lenalidomide (10 mg per day for the first 3 months, with a possible dose increase to 15 mg thereafter, depending on side effects) was initiated within the first 3 weeks after the completion of consolidation therapy and was continued for 1 year or until the occurrence of disease progression or unacceptable adverse events or the withdrawal of patient consent (whichever came first). For patients in the RVD-alone group, salvage transplantation was recommended at the time of disease progression. A list of permitted concomitant therapies is provided in the Supplementary Appendix, available at NEJM.org.
End Points
The primary end point was progression-free survival. Secondary end points included response rate, time to disease progression, overall survival, and adverse event rates. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Serious adverse events and interim efficacy analyses were reviewed by an independent data and safety monitoring committee.
Trial Oversight
The senior academic authors designed the trial and wrote the first draft of the manuscript. Investigators at Toulouse Hospital collected the data and performed the analyses in collaboration with the senior academic authors and an independent data and safety monitoring committee. All the authors vouch for the accuracy and completeness of the data and analyses and for the fidelity of the study to the trial protocol. Celgene and Janssen provided lenalidomide and bortezomib, respectively, and provided funding but had no role in the analysis or interpretation of the data. Editorial assistance in the preparation of this manuscript was provided by a member of the Investigator Initiated Research Writing Group (an initiative from Ashfield Healthcare Communications, UDG Healthcare) and was funded by Celgene.
Assessments
Treatment response and disease progression were assessed according to the International Uniform Response Criteria for Multiple Myeloma (see the Supplementary Appendix). 22 Complete disappearance of monoclonal protein (M protein) on standard clinical serum and urine immunofixation was considered to indicate a complete response if a bone marrow evaluation was performed and to indicate a very good partial response if a bone marrow evaluation was not performed. Blood and urine samples were obtained and immunofixation was performed every 4 weeks from randomization until disease progression. Among all the patients, bone marrow samples were obtained at enrollment for cytogenetic evaluation; among the patients who had a complete or very good partial response, bone marrow samples that had been obtained after the consolidation and maintenance phases were tested for minimal residual disease by means of seven-color flow cytometry (which has a sensitivity level of 10 −4 , indicating that it can detect 1 malignant plasma cell within 10,000 bone marrow cells). 20 Minimal residual disease was detected if at least 50 plasma cells were observed in the bone marrow. Patients who had disease progression were followed up every 3 months to determine survival status.
Statistical Analysis
Assuming a median progression-free survival of 30 months in the RVD-alone group and 39 months in the transplantation group, we estimated that 700 patients would need to be enrolled to provide the trial with at least 80% statistical power to detect a 9-month longer progression-free survival in the transplantation group than in the RVD-alone group, with the use of a two-sided log-rank test at an overall significance level of 0.05. The statistical power was adjusted for two interim analyses, which were performed after 33% and 69% of the estimated disease progression events had occurred. Critical values at interim analysis were determined with the use of Lan-DeMets error spending functions corresponding to O'Brien-Fleming stopping boundaries.
The second interim analysis was performed in June 2015. The results were submitted to the independent data and safety monitoring committee, who allowed the results to be presented publicly at that time because the difference in progression-free survival met the prespecified stopping criterion (P<0.015). Progression-free survival was defined as the time from randomization until either the first documentation of disease progression or death from any cause. Censoring rules for progression-free survival followed the Food and Drug Administration guidance on end points in cancer trials. Time to progression was defined as the time from randomization until either the first documentation of disease progression or death owing to myeloma. Overall survival was defined as the time from randomization until death from any cause. Duration of follow-up after randomization was estimated by means of the reverse Kaplan-Meier method.
T h e ne w e ngl a nd jou r na l o f m e dicine Time-to-event end points were analyzed by means of the Kaplan-Meier method, with the use of a two-sided stratified log-rank test to compare the treatment groups and a multivariate Cox proportional-hazards model adjusted for stratification factors to estimate adjusted hazard ratios and 95% confidence intervals. A competing-risk analysis was performed to assess the effect of censoring events on progression-free survival.
Analyses of progression-free survival in specific subgroups were prespecified in the statistical analysis plan and were performed with the use of Cox proportional-hazards models with terms for treatment group, subgroup, and the interaction between subgroup and treatment group. The interaction terms were evaluated for statistical significance. Response rates were compared between groups with the use of a chi-square test or Fisher's exact test. Incidence rates of second primary cancers were calculated as the ratio of the number of second primary cancers to the number of patient-years at risk and were compared between groups with the use of a binomial exact test. P values for secondary efficacy end points and subgroup analyses were separate ly adjusted for multiplicity testing with the use of the Holm procedure to control the family-wise error rate at 0.05. Analyses were prespecified in the statistical analysis plan and were performed according to the intention-to-treat principle, with the use of Stata software, version 14.0 (StataCorp); the data cutoff date was September 1, 2015 (set by the steering committee).
R esult s
Patients and Treatments
Of the 764 patients who were screened for eligibility, 57 did not meet the eligibility criteria. In addition, 7 of the patients who began the first cycle of RVD induction therapy did not undergo randomization (because of a decision by the patient or investigator [5 patients] or a severe adverse event [2 patients]). Thus, 700 patients underwent randomization; 350 were assigned to each treatment group. Baseline characteristics were well balanced between the two treatment groups (Table 1) .
In the RVD-alone group, 331 patients (95%) entered the consolidation phase and 321 (92%) entered the maintenance phase. In the transplantation group, 323 patients (92%) underwent transplantation, 315 (90%) began to receive RVD therapy after transplantation, and 311 (89%) entered the maintenance phase.
Response Rates
The rate of complete response was 48% in the RVD-alone group versus 59% in the transplantation group (P = 0.03). The rate of complete or very good partial response was 45% in the RVD-alone group versus 47% in the transplantation group after the induction phase (P = 0.87), 69% versus 78% after the consolidation phase (P = 0.03), and 76% versus 85% after the maintenance phase (P = 0.009); the rate was 70% after transplantation. Minimal residual disease was not detected in 65% of the patients in the RVD-alone group versus 79% of the patients in the transplantation group (P<0.001) ( Table 2) .
Progression-free Survival, Time to Progression, and Overall Survival
The median duration of follow-up after randomization was 44 months in the RVD-alone group and 43 months in the transplantation group. Disease progression or death occurred in 368 patients (211 in the RVD-alone group and 157 in the transplantation group). Data for 7.2% of the patients in the RVD-alone group and 9.8% of the patients in the transplantation group were censored because the patients received a new therapy or a therapy that was not specified in the protocol, had consent withdrawn, or were lost to follow-up (Table S1 in the Supplementary Appendix).
Median progression-free survival was 36 months in the RVD-alone group versus 50 months in the transplantation group (adjusted hazard ratio for disease progression or death, 0.65; 95% confidence interval [CI], 0.53 to 0.80; P<0.001) (Fig.  1A) . A competing-risk analysis led to numerically identical results (Fig. S1 in the Supplementary Appendix). Age, sex, isotype of the monoclonal component, International Staging System disease stage, and cytogenetic risk profile did not significantly modify the progression-free survival benefit associated with transplantation (Fig. 2) . Progression-free survival was longer among patients in whom minimal residual disease was not detected than among those in whom minimal residual disease was detected (adjusted hazard ratio for disease progression or death, 0.30; P<0.001) (Figs. S2A and S3 in the Supplementary Appendix).
The median time to progression was 36 months in the RVD-alone group versus 50 months in the transplantation group (adjusted hazard ratio for disease progression or death owing to myeloma, 0.62; P<0.001). Overall survival at 4 years did not differ significantly between the two groups; the rate was 82% in the RVD-alone group and 81% in the transplantation group (adjusted hazard ratio for death, 1.16; 95% CI, 0.80 to 1.68; P = 0.87) (Fig. 1B) . Median survival was not reached in either group. Overall survival was longer among patients in whom minimal residual disease was not detected than among those in whom minimal residual disease was detected (adjusted hazard ratio for death, 0.34; P<0.001) (Fig. S2B in the Supplementary Appendix).
Salvage Therapy
In the RVD-alone group, disease progression was reported in 207 patients, and 172 symptomatic Percentages may not total 100 because of rounding. † P values were adjusted for multiplicity with the use of the Holm procedure to control the family-wise error rate at 0.05. ‡ Minimal residual disease was detected by means of flow cytometry. As a result of decisions made by the patient or the investigator, 5 patients in the RVD-alone group and 29 patients in the transplantation group were not tested. Table S2 in the Supplementary Appendix.)
Adverse Events
The most common grade 3 or 4 adverse events are listed in Table 3 . In the RVD-alone group, treatment was discontinued in 32 patients (9%) because of adverse events, and two treatmentrelated deaths occurred. In the transplantation group, treatment was discontinued in 39 patients (11%) because of adverse events, and six treatment-related deaths occurred. Grade 3 or 4 adverse events that were significantly more common in the transplantation group than in the RVDalone group were blood and lymphatic-system disorders (95% vs. 64%, P<0.001), gastrointestinal disorders (28% vs. 7%, P<0.001), and infections (20% vs. 9%, P<0.001).
Second Primary Cancers
The incidence of second primary cancers did not differ significantly between the two treatment groups (Table S3 in the Supplementary Appendix). The incidence of invasive second primary cancers was 1.1 cases per 100 patient-years in the RVD-alone group and 1.5 cases per 100 patientyears in the transplantation group (P = 0.37). An updated analysis performed in September 2016 (Table S4 in the Supplementary Appendix) showed no significant between-treatment difference in the incidence of invasive second primary cancers (P = 0.36). Five cases of acute myeloid leukemia occurred: 1 in the RVD-alone group, and 4 in the transplantation group (P = 0.21).
Discussion
Before the introduction of immunomodulatory drugs and proteasome inhibitors, several randomized trials showed that high-dose chemotherapy plus autologous stem-cell transplantation was superior to conventional chemotherapy for the treatment of multiple myeloma. 1,2 In the consolidation phase of our trial, we compared highdose chemotherapy plus transplantation with RVD therapy, which consists of a combination of new agents, including lenalidomide and bortezo- Transplantation mib. We found that consolidation therapy with high-dose chemotherapy plus transplantation was associated with significantly longer progressionfree survival (the primary end point) than RVD therapy alone in patients with newly diagnosed myeloma. Transplantation was also associated with a higher rate of complete response, a lower rate of minimal residual disease detection, and a longer median time to progression. Overall survival was high and was similar in the two treatment groups. These results might be related to the use of RVD therapy in both treatment groups and to the high level of activity of the new agents that were used to treat relapses. 24 The similarity in overall survival in the two groups may also be related to the successful use of salvage transplantation. Several randomized trials that compared first-line transplantation with conventional chemotherapy, in which salvage transplantation was allowed, showed a progression-free survival benefit associated with first-line transplantation but no significant difference between treatments in overall survival. 3 Two recent studies in which transplantation was compared with an alkylating agent-based regimen plus lenalidomide followed by salvage transplantation showed an overall survival benefit associated with first-line transplantation. 25, 26 However, all these nontransplantation regimens did not include proteasome inhibitors, have not been shown to lead to higher survival rates than those with melphalan-prednisone, 27 and resulted in poorer outcomes than those associated with transplantation. Data from our study suggest that delayed transplantation is feasible and is associated with no decrement in overall survival.
We found that the rate at which minimal residual disease was detected was lower among patients who received RVD plus transplantation than among those who received RVD alone. In addition, we observed longer overall survival among patients in whom minimal residual disease was not detected than among those in whom it was detected, regardless of treatment assignment. These findings confirm that the absence of minimal residual disease is an important treatment target in myeloma 28, 29 and suggest that the use of high-dose chemotherapy plus transplantation after induction therapy with RVD specifically among patients in whom minimal residual RVD therapy consists of lenalidomide, bortezomib, and dexamethasone. The P values shown have not been adjusted for multiple comparisons; P = 1.00 after adjustment for multiple comparisons in each subgroup. T h e ne w e ngl a nd jou r na l o f m e dicine disease is detected could be evaluated in future trials as one particular approach to tailoring therapy and further improving clinical benefit. In our trial, minimal residual disease was assessed by means of seven-color flow cytometry (sensitivity level, 10 −4 ). 20 It is possible that the more sensitive next-generation flow cytometry could have revealed more subtle differences and that patients in whom minimal residual disease was not detected in our trial may be considered to be patients in whom minimal residual disease is detected according to the new International Myeloma Working Group criteria. 30 Maintenance treatment with lenalidomide after transplantation significantly improves outcomes among patients with newly diagnosed myeloma. 31, 32 However, the duration of maintenance therapy remains a matter of debate. In our trial, maintenance therapy was administered for 1 year to limit toxic effects. In an ongoing, collaborative, parallel U.S. trial (the DETERMINATION study; ClinicalTrials.gov number, NCT01208662), which has a similar design to our trial, maintenance therapy with lenalidomide is being administered continuously until disease progression. A comparison of these two parallel trials will shed further light on this important question.
Grade 3 and 4 adverse events were more common with RVD plus transplantation than with RVD alone (97% vs. 83%). Five cases of acute myeloid leukemia occurred: four in the transplantation group, and one in the RVD-alone group. Although acute myeloid leukemia is part of the natural history of myeloma and its treatment, particularly in the context of melphalan use, 33 the patients in the transplantation group will require longer follow-up to accurately quantify this important risk.
In conclusion, we found that consolidation therapy with high-dose chemotherapy plus transplantation was associated with longer progressionfree survival than RVD therapy alone. This benefit must be weighed against the increased risk of toxic effects associated with high-dose chemotherapy plus transplantation, especially since we found that later transplantation might be as effective as early transplantation in securing longterm survival. Our results suggest that the use of a combination therapy that incorporates newer proteasome inhibitors, next-generation immunomodulatory drugs, and potent monoclonal antibodies along with transplantation tailored according to minimal residual disease detection could further improve outcomes among adults up to 65 years of age who have multiple myeloma. [34] [35] [36] [37] [38] Supported by grants from Celgene and Janssen and by funds from the French Ministry of Health Programme Hospitalier de Recherche Clinique and from the French National Research Agency (project ANR-11-PHUC-001-CAPTOR).
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